Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary View
Toggle Summary Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Submission to EMA follows Biologics Licensing Application submission to U.S. FDA earlier this month SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2019-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing
View HTML
Toggle Summary Acceleron Announces Departure of Chief Medical Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 5, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that Robert K.
View HTML
Toggle Summary Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications EMA marketing application for both indications planned for Q2:19 SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 5, 2019-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc.
View HTML
Toggle Summary Acceleron Discontinues Development of Phase 1 Molecule ACE-2494
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 4, 2019-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a
View HTML
Toggle Summary Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (
View HTML
Toggle Summary Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
- MEDALIST and BELIEVE Phase 3 trial presentations at the 60 th American Society of Hematology (ASH) Annual Meeting both selected for “Best of ASH” - - Luspatercept Biologics License Application (BLA) submission expected in April 2019 - - Part 2 results from the ACE-083 Phase 2 trials in
View HTML
Toggle Summary Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 19, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results.
View HTML
Toggle Summary Acceleron to Present at Two Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two
View HTML
Toggle Summary Acceleron Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 16, 2019-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced
View HTML
Toggle Summary Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 14, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it
View HTML